EGFRt/19-28z/IL-12 CAR T Cells
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for EGFRt/19-28z/IL-12 CAR T Cells, covering 2025-08-03 to 2025-08-03. Get the full timeline:
Most recent: Clinical Trial Update: Genetically Engineered Cells (EGFRt/19-28z/IL-12 CAR T Cells) for the Treatment of Relapsed or Refractory CD19+ Hematologic Malignancies [Phase 1]